Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
AORT filed a notice under Section 144 reporting an intended sale of 2,075 common shares tied to restricted stock vesting on 02/23/2026.
The filing also discloses a prior sale of 3,773 common shares on 02/23/2026 for $141,817.64, and identifies Fidelity Brokerage Services LLC as the broker on 02/24/2026.
AORT reported a proposed resale of 4,485 shares of common stock. The filing states these 4,485 shares arise from restricted stock vesting received as compensation on 02/23/2026.
The filing also lists 4,981 shares of common stock sold during the prior three months on 02/23/2026, with an aggregate amount of $187,223.34.
Jean Holloway filed a Form 144 indicating an intended sale of 1,668 shares of common stock related to restricted stock vesting on 02/23/2026, with a reported aggregate value of $59,535.76.
The filing also reports prior sales during the past three months of 3,079 shares on 02/23/2026 with aggregate proceeds of $115,731.92.
AORT insider filing reports proposed and recent share dispositions by James P. Mackin. The notice lists a proposed sale of 13,936 common shares delivered on 02/23/2026 tied to restricted stock vesting and shows three reported sales in the prior three months: 30,921 shares on 12/02/2025 for $1,408,736.02, 30,921 shares on 12/03/2025 for $1,405,693.40, and 20,962 shares on 02/23/2026 for $787,909.17.
Marshall Stanton reported an intended sale of Common shares. The Form 144 lists 2,423 shares with a value of 91074.51 dated 02/23/2026. The entry is tied to Restricted Stock Vesting and classified as Compensation.
Amy Horton filed a Rule 144 notice reporting proposed and recent sales of common stock of AORT. The filing lists a proposed sale of 830 common shares on 02/23/2026 described as Restricted Stock Vesting (Issuer, Compensation). It also records prior sales of 4,572 shares on 12/08/2025 for $203,081.38 and 1,731 shares on 02/23/2026 for $65,063.96.
AORT reported a Form 144 disclosing planned sales of common stock tied to a restricted stock vesting event. The filing lists 1,731 shares associated with the vesting on 02/20/2026 and shows prior sales of 4,572 shares on 12/08/2025 for $203,081.38.
The sale activity is routed through Fidelity Brokerage Services LLC (address shown) and is recorded in the filing as compensation-related vesting. Timing and detailed plan-of-distribution mechanics beyond the vesting date are not included in the excerpt.
James Mackin reported proposed sales of common stock under a Form 144. The filing lists 20,962 shares to be sold in connection with restricted stock vesting on 02/20/2026. The filing also shows prior sales of 30,921 shares on 12/02/2025 for $1,408,736.02 and 30,921 shares on 12/03/2025 for $1,405,693.40.